EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia

Fabio Efficace iD, Francesco Cottone, Betina Yanez iD, Vamsi Kota iD, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio iD, Andrea Patriarca, Isabella Capodanno, Maria Cristina Miggiano, Mario Tiribelli iD, Massimo Breccia iD und 11 weitere

Cancer · 2024-01 · 130 (2) · 287-299

DOI: 10.1002/cncr.35021 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Cancer, online erschienen am 06.10.2023. Verfasst von Fabio Efficace und 22 weiteren Autor:innen. Beteiligte Einrichtung: Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health/National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The authors assessed the clinical utility of patient‐reported symptom monitoring in the setting of newly diagnosed chronic myeloid leukemia (CML). The primary objective was to evaluate adherence to therapy.

Methods

The authors conducted an international prospective study that included patients with newly diagnosed, chronic‐phase CML. Before clinical consultation, patients were provided a tablet computer to self‐rate their symptoms, and the results were available in real time to each physician during the patient’s visit. Adherence was assessed by pill count and with a validated self‐reported questionnaire. The proportions of optimal responders at 3 and 6 months were assessed according to the European LeukemiaNet criteria.

Results

Between July 2020 and August 2021, 94 patients with a median age of 57 years were enrolled. Pill count adherence analysis indicated that 86 of 93 evaluable patients (92.5%) took at least 90% of prescribed tyrosine kinase inhibitor therapy during the 6‐month observation period. The online platform was well accepted by patients and physicians. An optimal response was achieved by 69 of 79 patients (87.3%) at 3 months and by 61 of 81 patients (75.3%) at 6 months.

Conclusions

Patient‐reported symptom monitoring from the beginning of therapy in patients with CML may be critical to improve adherence to therapy and early molecular response rates (ClinicalTrials.gov identifier NCT04384848).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansMiddle AgedChronic DiseaseMedication AdherencePatient Reported Outcome MeasuresProspective Studies

Stichwörter der Autor:innen

adherencechronic myeloid leukemiadigital healthmolecular responsequality of lifesymptoms

Autor:innen und Institutionen

  • Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
  • Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Georgia Cancer Center, Augusta University Medical Center, Augusta, Georgia, USA.
  • Hematology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Department of Medical Sciences and Public Health, University of Cagliari, Businco Hospital, Cagliari, Italy.

ORCID-Profile: Fabio Efficace, Betina Yanez, Vamsi Kota, Massimiliano Bonifacio, Mario Tiribelli, Massimo Breccia, Alessandra Iurlo, Elisabetta Abruzzese

Förderung

  • NCI NIH HHS
  • National Institutes of Health/National Cancer Institute

Zitieren

APA

Efficace, F., Cottone, F., Yanez, B., Kota, V., Castagnetti, F., Caocci, G., Bonifacio, M., Patriarca, A., Capodanno, I., Miggiano, M. C., Tiribelli, M., Breccia, M., Luciano, L., Giai, V., Iurlo, A., Abruzzese, E., Fava, C., Dinner, S., Altman, J. K., …, & Cella, D. (2024). Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. Cancer, 130(2), 287-299. https://doi.org/10.1002/cncr.35021

Vancouver

Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, et al. Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. Cancer. 2024;130(2):287-299. doi:10.1002/cncr.35021

BibTeX
@article{Efficace2024,
  author = {Efficace, Fabio and Cottone, Francesco and Yanez, Betina and Kota, Vamsi and Castagnetti, Fausto and Caocci, Giovanni and Bonifacio, Massimiliano and Patriarca, Andrea and Capodanno, Isabella and Miggiano, Maria Cristina and Tiribelli, Mario and Breccia, Massimo and Luciano, Luigia and Giai, Valentina and Iurlo, Alessandra and Abruzzese, Elisabetta and Fava, Carmen and Dinner, Shira and Altman, Jessica K and Rosti, Gianantonio and Cortes, Jorge and Vignetti, Marco and Cella, David},
  title = {Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {2},
  pages = {287--299},
  doi = {10.1002/cncr.35021}
}
Kostenlos starten →